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FibrosisVascular smoothmuscle cell (VSMC) proliferation and vascular ﬁbrosis are closely linkedwith hypertension and
atherosclerosis. Salusin-β is a bioactive peptide involved in the pathogenesis of atherosclerosis. However, it is still
largely undeﬁned whether salusin-β is a potential candidate in the VSMC proliferation and vascular ﬁbrosis.
Experiments were carried out in human vascular smooth muscle cells (VSMCs) and in rats with intravenous in-
jection of lentivirus expressing salusin-β. In vitro, salusin-β promoted VSMCs proliferation, which was attenuat-
ed by adenylate cyclase inhibitor SQ22536, PKA inhibitor Rp-cAMP, epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor AG1478, ERK inhibitor U0126 or cAMP response element binding protein (CREB) inhib-
itor KG501. It promoted the phosphorylation of ERK1/2, CREB and EGFR, which were abolished by SQ22536 or
Rp-cAMP. Furthermore, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 diminished
the salusin-β-evoked ERK1/2 and CREB phosphorylation. On the other hand, salusin-β increased collagen-I,
collagen-III, ﬁbronectin and connective tissue growth factor (CTGF) mRNA and phosphorylation of Smad2/3,
which were prevented by ALK5 inhibitor A83-01. In vivo, salusin-β overexpression increased the media thick-
ness, media/lumen ratio coupled with ERK1/2, CREB, EGFR and Smad2/3 phosphorylation, as well as the mRNA
of collagen-I, collagen-III, ﬁbronectin, transforming growth factor-β1 (TGF-β1) and CTGF in arteries. Moreover,
salusin-β overexpression in rats caused severe hypertension. Intravenous injection of salusin-β dose-relatedly in-
creased blood pressure, but excessive salusin-β decreased blood pressure and heart rate. These results indicate
that salusin-β promotes VSMC proliferation via cAMP-PKA-EGFR-CREB/ERK pathway and vascular ﬁbrosis via
TGF-β1-Smad pathway. Increased salusin-β contributes to vascular remodeling and hypertension.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Proliferation of vascular smooth muscle cells (VSMCs) and vascular
ﬁbrosis are closely linked with many clinical diseases including hyper-
tension, atherosclerosis and diabetes and their target organ damage
[1,2]. Excess synthesis and accumulation of extracellular matrix (ECM)ptor-likekinase5;Ang II, angio-
onse element binding protein;
matrix; EGF, epidermal growth
F-like growth factor; HR, heart
saline; SBP, systolicbloodpres-
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ascular Disease and Molecular
cal University, 140 Hanzhong
.mainly in the vascular wall responses to chronically elevated blood
pressure induces vascular stiffening, which reinforce the development
of hypertension, thus reﬂecting a vicious circle [3,4]. The indices of
small resistance artery structure, such as the tunica media to internal
lumen ratio may have a strong prognostic signiﬁcance in hypertensive
and diabetic patients [5,6].
Salusins are identiﬁed to be peptides of 28 and 20 amino acids with
peripheral hypotensive, bradycardic and mitogenic effects, and to be
designated as salusin-α and salusin-β in 2003. They are translated
fromanalternatively splicedmRNAof TOR2A, a gene encoding a protein
of the torsion dystonia family [7]. The initial 18 amino acids of human
salusin-β have high homology with the estimated N-terminal sequence
of rat salusin, but human salusin-α have a very big difference in the se-
quence compared with rat salusin [8]. Central salusin-β contributed to
sympathetic activation, arginine vasopressin release and hypertension,
and plasma salusin-β level was increased in renovascular hypertensive
rats [9–12]. Plasma salusin-β levels in subjects with diabetes mellitus,
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higher levels than healthy controls, and it may be taken as an indicator
of systemic vascular diseases [13]. Salusin-β immunoreactivity
was found to be dominant in the VSMCs and ﬁbroblasts in coronary
atherosclerotic lesions rather than salusin-α. Salusin-β promoted but
salusin-α suppressed the formation of human macrophage foam cells
in atherosclerosis. We hypothesized that salusin-β contributes to the
VSMCs proliferation and vascular ﬁbrosis. In this study, we determined
the effects of salusin-β on VSMCs proliferation and vascular ﬁbrosis and
their downstream signal pathway in human VSMCs. Lentivirus vectors
encoding salusin-β were constructed in rats to determine the effects
of persistently increased salusin-β on the vascular remodeling and
blood pressure.
2. Materials and methods
2.1. Cell culture
Human aortic vascular smooth muscle cells (VSMCs) were pur-
chased from American Type Culture Collection (Rockville, MD, USA)
and were cultured in F12K Kaighn’s modiﬁcation medium supplement-
ed with 10% fetal bovine serum (FBS) and 1 × Antibiotic-Antimycotic
Solution at 37 °C, humidiﬁed atmosphere containing 5% CO2. The
growth medium was replaced every 3-4 day and the cells were seeded
onto petridishes or multiwell plates at a ratio of 1 to 4 upon 80% conﬂu-
ence, andwere starved for 24 h in serum-free medium prior to use [14].
2.2. Animals
Total 66male Sprague-Dawley ratsweighing between250 and 300 g
were used in the experiments. Procedures were approved by the Exper-
imental Animal Care and Use Committee of Nanjing Medical University
and conformed to the Guide for the Care and Use of Laboratory Animal
published by the US National Institutes of Health (NIH publication, 8th
edition, 2011). The rats were housed on a 12-h light/dark cycle in a
temperature-controlled room with standard chow and tap water ad
libitum. Surgery for blood pressure recordingwas carried out under an-
esthesia with intraperitoneal injection of urethane (800 mg/kg) and a-
chloralose (40 mg/kg). The depth of anesthesia was determined by
the absence of corneal reﬂexes and paw withdrawal response to a
noxious pinch [11]. At the end of the experiment, the rats were eutha-
nized with an overdose of pentobarbital sodium (150 mg/kg, iv).
2.3. VSMCs proliferation assay
Cell counting kit-8 kits (CCK-8, Beyotime Institute of Biotechnology,
Shanghai, China) were used for evaluation VSMC proliferation. Accord-
ing to themanufacturer’s instructions, cell growthwas arrested by incu-
bation of the cells in serum-freemedium for 24 h prior to be used. Then,
VSMCs were seeded onto a 96-well cell culture plate at a density of
2 × 103 cells/well for 24 h at 37 °C, and treatedwith different concentra-
tions of salusin-β for 24, 48 or 72 h. Finally, 10 μl of CCK-8 solution was
added into eachwell, and incubated for 2 h at 37 °C. The absorbancewas
conducted at 450 nm using a microplate reader (ELX800, BioTek,
Vermont, USA).
2.4. Cell cycle analysis and EdU incorporation assay
The distribution of various phases of the cell cycle was used to eval-
uate the VSMCs proliferation with ﬂow cytometry. Simply, VSMCswere
plated in six-well plates at a density of 1 × 105/well and were synchro-
nized with 24 h of serum starvation. The medium was changed to
serum-free basal medium for the next 24 hours. VSMCswere then incu-
bated with PBS or salusin-β for 48 hours. The cells were washed twice
with phosphate-buffered saline (PBS) and were digested with trypsin.
After collection by centrifugation, the samples were mixed in ice-cold70% ethanol overnight at -20 °C. Before measurement, cells were
washed again and re-suspended in PBS containing 50 μg/ml RNase A
and 50 μg/ml propidium iodide for 30 minutes at room temperature in
the dark. The intracellular ﬂuorescence intensity in each sample was
measured using a ﬂow cytometer (Becton-Dickinson Biosciences, San
Jose, CA, USA) and the results were expressed as the percentage of
cells in each cell cycle phase for cell cycle analysis.
EdU incorporation assaywas employed to determine VSMC prolifer-
ation with In Vitro Imaging Kit (Guangzhou RiboBio, Guangzhou,
China). The DNA synthesis of VSMCs was measured using a Cell-
Light™ EdU Apollo®488. The EdU positive cells were counted and nor-
malized by the total number of Hoechst 33342 stained cells.
2.5. Measurement of salusin-β
Commercial ELISA kit was used for the measurement of salusin-β
(Uscn Life Science, Houston, TX, USA). As we previously reported [10],
the standards or sample diluent were added and incubated in the
appropriate well of speciﬁc antibody pre-coated microtiterplate.
Conjugate was added and incubated for 1 h at 37 °C and then washed.
The reactions were stopped with stop solution and read at 450 nm by
using a microtiter plate reader (ELX800, BioTek, Vermont, USA).
2.6. Western blot analysis
The phosphorylation of ERK1/2, JNK, p38, PKA, histone H3, cAMP re-
sponse element binding protein (CREB), epidermal growth factor recep-
tor (EGFR) and Smad2/3 were determined with Western blot. Brieﬂy,
VSMCs or tissues were sonicated in RIPA lysis buffer and homogenized.
The debris was removed and supernatant was obtained by centrifuga-
tion at 12,000 g for 10 min at 4 °C. Total protein concentration was de-
termined to ensure that the equal loading of proteins was separated on
8% or 10% SDS-PAGE and transferred onto PVDF membrane. The mem-
brane was blocked with 5% non-fat milk in TBST and then probed with
the desired primary antibody at 4 °C overnight followed by incubation
with appropriate HRP-linked secondary antibody. The protein expres-
sionswere visualized by enhanced chemiluminescence. GAPDH protein
served as a loading control.
2.7. Real-time quantitative PCR analysis
The mRNA of collagen-I, collagen-III, ﬁbronectin, transforming
growth factor-β1 (TGF-β1) and connective tissue growth factor
(CTGF) were analyzed by real-time quantitative PCR. The total RNA
was isolated by using Trizol reagent according to themanufacturer’s in-
structions. The mRNA concentration in each sample was measured and
0.5 μg of total RNA was reverse transcribed to cDNA. Quantitative PCR
with SYBR Premix Ex Taq TM (Takara, Otsu, Shiga, Japan) was performed
in triplicates by reacting with strand-speciﬁc primers, and the average
cycle thresholds (Ct) were used to determine fold-change. The relative
quantiﬁcation of gene expression was shown as a relative quantity to
the control value. The sequences of primers for human VSMCs and
rats were listed in the supplemental tables (Tables S1 & S2, in the
online-only Data Supplement).
2.8. Measurement of cAMP level
Samples were pre-incubated with 1 mM of 3-isobutyl-1-
methylxanthine (IMBX), a phosphodiesterase inhibitor, for 30 min to
prevent the degradation of accumulated cAMP. The intracellular cAMP
levels were determined by an enzyme immunoassay kit (R&D Systems
Inc., Minneapolis, MN, USA) following the manufacturer’s instructions.
Total protein concentration in the homogenate was measured with a
protein assay kit (Santa Cruz, Dallas, TX, USA).
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Recombinant lentivirus expressing salusin-β or green ﬂuorescent
protein (GFP) vector was designed and identiﬁed by Invitrogen
(Life Tech, Shanghai, China). Complementary sequences of oligo DNA




was annealed and subcloned to the enzyme-digested pLenti6.3-IRES2-
GFP vector, and then the connected compound was transinfected with
competent cell DH5α. The recombinant plasmid was sequenced to
verify whether insert sequences were consistent with oligo DNA se-
quences. A packaging plasmid system pLP1,pLP2 and pLP/VSVG were
co-transfected into 293FT cells via Lipofectamine 2000. The transfected
cells were incubated for 6 h, and then the complete medium was re-
placed. The viral particles were subsequently harvested at 48 h after
transfection, 0.45-μmcellulose acetate ﬁlter was used to remove the de-
bris, under centrifugation at 50,000 rpm (4 °C) for 2 h and resolved in
formulation buffer. The titer of virions was determined through the
transduction of HEK293 cells with serial dilutions of the vector and
GFP expression assessment by ﬂuorescent cells counting under ﬂuores-
cence microscopy after 96 h. GFP-expressing vector was used as a con-
trol. Viral stocks were aliquoted and stored until they were used.
Rats were randomly divided into control (Ctrl), Vector and Salusin-β
groups, whichwere respectively subjected to injection of PBS, lentivirus
expressing GFP or lentivirus expressing both GFP and salusin-β (1 × 108
TU/ml, 100 μl) via tail vein. Acute experiments were performed 4weeks
after the introduction.
2.10. Masson’s trichrome staining
The descending thoracic aorta,main renal artery and the third-order
branches of the mesenteric artery were obtained and ﬁxed in 4% para-
formaldehyde in PBS, embedded in parafﬁn, sectioned into 5-μm thick,
and stainedwithMasson’s trichrome staining [15]. Vascular remodeling
was analyzed under light microscopy (BX 45, Olympus Corporation,
Tokyo, Japan).
2.11. Preparation for tunicae media of vasorum
Removal of adventitia and tunica intima was made to isolate the tu-
nicaemedia in three graded-arteries. In short, ratswere sacriﬁced under
overdose of anesthesia, the descending thoracic aorta, main renal artery
and the third-order branches of the mesenteric artery were dissected
and washed by cold PBS for three times. Connective tissues afﬁliated
to vessels were cleaned, and the endothelium was denuded via gentle
rubbing, then the adventitia was carefully removedwith forceps as pre-
viously described [16–19].
2.12. Measurement of blood pressure
Systolic blood pressure (SBP) of tail arterywasmeasured in conscious
state by using a noninvasive computerized tail-cuff system (NIBP,
ADInstruments, Sydney, New South Wales, Australia). The rats were
warmed for 10-20 min at 28 °C before the measurements in order to
allow detection of tail artery pulsations and to achieve the steady pulse
level. SBP was obtained by averaging 10 measurements [11,20]. Mean
arterial pressure (MAP) and heart rate (HR) were recorded under
anesthesia with intraperitoneal injection of urethane (800 mg/kg) and
a-chloralose (40 mg/kg).
2.13. Chemicals
Antibodies of ERK1/2, JNK1/2, p38, CREB, PKA and their phosphory-
lated forms were purchased from Cell Signaling Technology Inc.(Danver, MA, USA). Antibodies of EGFR, Smad2/3, TGF-β1 and their
phosphorylated forms as well as PCNA and phosphorylated histone H3
were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).
Antibody of salusin-β was purchased from Bachem (Bubendorf,
Switzerland). Antibody of salusin-α was purchased from Abcam
(Cambridge, MA, USA). Antibody of HB-EGF was purchased from R&D
Systems (Minneapolis, Minn, USA). Salusin-β was purchased from
Phoenix Pharmaceuticals (CA, USA). SQ22536, Rp-cAMP, KG501,
AG1478, A83-01, RNase A and propidium iodide were obtained from
Sigma Chemical Co. (St Louis, MO, USA). SP600125, SB203580 and
U0126 were purchased from Calbiochem (San Diego, California,USA).
F12K Kaighn’s modiﬁcation medium and smooth muscle cell growth
supplement (SMGS) were obtained from Cascade Biologics (Portland,
OR, USA). The concentration of inhibitors used in the present study
was determined according to previous studies and our preliminary
studies.
2.14. Statistical analysis
Comparisons between two groups were made by Student’s t test.
One-way or two-way ANOVA followed by post hoc Bonferroni test
was used when multiple comparisons were made. All data were
expressed as mean± SE. A value of P b 0.05was considered statistically
signiﬁcant.
3. Results
3.1. Proliferation in human VSMCs
Salusin-β dose-relatedly promotes VSMCs proliferation, reaching its
maximal effects at the concentration of 10 nmol/L at 48 h after salusin-β
treatment (Fig. 1A). The proliferation effect of salusin-βwas prevented
by anti-salusin-β IgG, but not by anti-salusin-α IgG. Either anti-salusin-
α or anti-salusin-β IgG had no signiﬁcant effects on basal VSMCs prolif-
eration (Fig. 1B). Salusin-β reduced the cell populations in the G0/G1
phases and increased those in the S phase comparedwith vehicle treat-
ment in VSMCs (Fig. 1C), and increased Edu-positive cells in VSMCs
(Fig. 1D). The speciﬁcity of salusin-β in promoting the proliferation of
VSMCs was supported by the fact that an equal concentration of scram-
bled peptide of salusin-β failed to promote proliferation (Fig. S1, in the
online-only Data Supplement).
3.2. Signal pathway of proliferation in human VSMCs
Salusin-β increased cAMP levels in VSMCs (Fig. 2A). It promoted the
phosphorylation of PKA, which was abolished by an adenylate cyclase
(AC) inhibitor SQ22536 (Fig. S2, in the online-only Data Supplement).
The effect of salusin-β on proliferation was prevented by SQ22536,
PKA inhibitor Rp-cAMP, EGFR tyrosine kinase inhibitor AG1478
(Fig. 2B), ERK inhibitor U0126 or CREB inhibitor KG501, but not by
JNK inhibitor SP600125 or p38 inhibitor SB203580 (Fig. 2C). Further-
more, salusin-β promoted the ERK1/2 phosphorylation, reaching its
maximal effect at 30 min and lasting at least 2 h (Fig. 3A,C), which
was abolished by the pretreatment with SQ22536, Rp-cAMP or
AG1478 (Fig. 3B,D). The maximal phosphorylation effect of salusin-β
is 10 nmol/L (Fig. S3, in the online-only Data Supplement). Moreover,
salusin-β promoted the phosphorylation of CREB and EGFR, which
were abolished by the pretreatment with SQ22536, Rp-cAMP or
AG1478 (Fig. 3B,D). However, salusin-β had no signiﬁcant effect on
the phosphorylation of JNK and p38 (Fig. 3A,C). On the other hand, neu-
tralization of EGF with anti-HB-EGF IgG prevented the salusin-β-
induced proliferation of VSMCs (Fig. S4, in the online-only Data Supple-
ment). It attenuated the salusin-β-induced EGFR phosphorylation, and
prevented the salusin-β-induced phosphorylation of CREB and ERK
(Fig. S5, in the online-only Data Supplement). Activin receptor-like ki-
nase 5 (ALK5) is recognized as a type I receptor of TGF-β. ALK5 inhibitor
Fig. 1. Effects of salusin-β on VSMCs proliferation. A, effects of different concentration of salusin-β (0.01, 0.1, 1, 10 and 100 nmol/L) treated for 0, 24, 48 and 72 h on VSMCs proliferation
determinedwith CCK-8 kits; B, effects of anti-salusin-α IgG (10mg/L) and anti-salusin-β IgG (10mg/L) on the VSMCs proliferation response to salusin-α or salusin-β (10 nmol/L) treated
for 48 h. IgGwas administered 30min before salusin-β treatment; C, effects of salusin-β (10 nmol/L) treated for 48 h onVSMCs proliferation evaluated by the distribution of various phases
in cell cycle determined with ﬂow cytometry; D, effects of salusin-β (10 nmol/L) treated for 48 h on DNA synthesis in VSMCs determined with EdU incorporation assay. The data were
expressed as a ratio of EdU-positive cells to total cells. Blue ﬂuorescence (Hoechst 33342) shows cell nuclei and green ﬂuorescence (Edu) stands for cells with DNA synthesis (×200).
Values are mean ± SE. *P b 0.05 vs. vehicle (Veh); †P b 0.05 vs. salusin-β. n = 6 for each group.
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β in VSMCs (Fig. S6, in the online-only Data Supplement).
3.3. Fibrosis in human VSMCs
Salusin-β increased the collagen-I, collagen-III and ﬁbronectin
mRNA expressions in VSMCs, which were abolished by anti-salusin-β
IgG, and not by anti-salusin-α IgG. Either anti-salusin-α or anti-
salusin-β IgG had no signiﬁcant effect on VSMCs ﬁbrosis (Fig. 4A). An
equal concentration of scrambled peptide of salusin-β failed to promote
ﬁbrosis, supporting the speciﬁcity of salusin-β in promoting ﬁbrosis of
VSMCs (Fig. S7, in the online-only Data Supplement).
3.4. Signal pathway of ﬁbrosis in human VSMCs
ALK5 inhibitor A83-01 prevented the effect of salusin-β on collagen-
I, collagen-III and ﬁbronectin mRNA expressions in VSMCs (Fig. 4B).
Salusin-β promoted the phosphorylation of Smad2/3 (Fig. 4C,E) and in-
creased the CTGF mRNA expression, which were abolished by A83-01
(Fig. 4D). Moreover, neutralization of TGF-β1 with anti-TGF-β1 IgG
abolished the effects of salusin-β on collagen-I, collagen-III and ﬁbro-
nectin mRNA expressions as well as Smad2/3 phosphorylation in
VSMCs (Figs. S8 and S9, in the online-only Data Supplement). In addi-
tion, salusin-β increased TGF-β1 mRNA expression (Fig. 4D).3.5. Interaction of salusin-β and salusin-α in human VSMCs
Salusin-α showed a weaker effect in promoting VSMCs proliferation
than salusin-β (Fig. S10, in the online-only Data Supplement). The effect
of salusin-α was abolished by anti-salusin-α IgG, and not by anti-
salusin-β IgG (Fig. S11, in the online-only Data Supplement). Combined
application of salusin-β and salusin-α caused a much greater effect on
VSMCs proliferation than the same concentration of salusin-β or
salusin-α alone (Fig. S12, in the online-only Data Supplement).
Salusin-α had no signiﬁcant effect on basal collagen-I, collagen-III and
ﬁbronectin mRNA expressions in VSMCs (Fig. S13, in the online-only
Data Supplement), but signiﬁcantly reduced the salusin-β-induced
collagen-I, collagen-III and ﬁbronectin mRNA expressions in VSMCs
(Fig. S14, in the online-only Data Supplement).3.6. Salusin-β levels and vascular remodeling in rats with salusin-β
overexpression
Salusin-β levels in aorta, renal artery and mesentery artery
were higher in rats with salusin-β overexpression than control rats
(Fig. 5A). The plasma salusin-β level in rats with salusin-β overexpres-
sion was increased to 6-8 folds of those in control rats (Fig. 5B).
Signiﬁcant GFP protein expression was found 3 days after the viral
Fig. 2. Effects of salusin-β on cAMP levels and effects of pretreatment with a variety of inhibitors on VSMCs proliferation response to salusin-β. Measurements were carried out 48 h after
the treatment with salusin-β (10 nmol/L). All the pretreatments were administered 30 min before salusin-β treatment. A, effects of salusin-β on cAMP levels; B, effects of pretreatment
with vehicle (Veh), SQ22536 (adenylate cyclase inhibitor, 300 μmol/L), Rp-cAMP (PKA inhibitor, 200 μmol/L) and AG1478 (EGFR tyrosine kinase inhibitor, 5 μmol/L) on the VSMCs pro-
liferation response to salusin-β; C, effects of treatment with Veh, SP600125 (JNK inhibitor, 10 μmol/L), U0126 (ERK inhibitor, 10 μmol/L), SB203580 (p38 inhibitor, 10 μmol/L), KG501
(CREB inhibitor, 25 μmol/L), or (KG501 + U0126) on the VSMCs proliferation response to salusin-β. Values are mean ± SE. *P b 0.05 vs. Veh or Veh + Veh; †P b 0.05 vs.
Veh + salusin-β. n = 6 for each group.
Fig. 3. Effects of salusin-β on the phosphorylation of JNK, ERK1/2, p38, CREB and EGFR, and effects of treatment with a variety of inhibitors on the phosphorylation response to salusin-β in
VSMCs. Measurements were carried out after the treatment with salusin-β (10 nmol/L) for 30 min. All the pretreatments were administered 30 min before salusin-β treatment. A, time
effect of salusin-β on the JNK, ERK 1/2and p38 phosphorylation; B, effects of salusin-β on the ERK, CREB and EGFR phosphorylation, as well as the effects of SQ22536 (adenylate cyclase
inhibitor, 300 μmol/L), Rp-cAMP (PKA inhibitor, 200 μmol/L) or AG1478 (EGFR tyrosine kinase inhibitor, 5 μmol/L) on the phosphorylation response to salusin-β; C, representative images
of Western blot showing the time effects of salusin-β on the phosphorylation of JNK, ERK1/2 and p38; D, representative images of Western blot showing the effects of salusin-β and a
variety of inhibitors on the phosphorylation of ERK, CREB and EGFR. Values are mean ± SE. *P b 0.05 vs. 0 min; †P b 0.05 vs. Veh; ‡ P b 0.05 vs. salusin-β. n = 4 for each group.
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Fig. 4.Effects of salusin-β and an ALK5 inhibitor A83-01 onVSMCsﬁbrosis.Measurementswere carried out 48h after the treatmentwith salusin-β (10 nmol/L). All the pretreatmentswere
administered 30min before salusin-β treatment. A, collagen-I, collagen-III and ﬁbronectinmRNA expressions and effects of anti-salusin-α IgG and anti-salusin-β IgG; B, effects of A83-01
(1 μmol/L) on collagen-I, collagen-III and ﬁbronectinmRNA expressions; C, phosphorylation of Smad2/3; D, TGF-β1 and CTGFmRNA expressions; E, representative images ofWestern blot
showing the Smad2/3phosphorylation. Values are mean ± SE. *P b 0.05 vs. vehicle (Veh); †P b 0.05 vs. Veh + Salusin-β. n = 4 for each group.
Fig. 5. Effects of salusin-β overexpression on salusin-β levels and remodeling of arteries in rats. All themeasurements were carried out 4weeks after the rats received PBS (Ctrl), lentivirus
expressing GFP (Vector), or lentivirus expressing both GFP and salusin-β (Salusin-β). A, salusin-β levels in aorta, renal artery and mesentery artery; B, plasma salusin-β levels; C, media
thickness, lumen diameter and their ratio of arteries; D, representative images ofMasson’s trichrome staining showing the remodeling of arteries. Values aremean± SE. *P b 0.05 vs.Ctrl;
†P b 0.05 vs. Vector. n = 6 for each group.
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1715H.-J. Sun et al. / Biochimica et Biophysica Acta 1852 (2015) 1709–1718delivery in rats with salusin-β overexpression and reached its maximal
at 2 weeks, lasting at least 4 weeks (Fig. S15, in the online-only Data
Supplement). The green ﬂuorescence of GFP was primarily found
in arteries (Fig. S16, in the online-only Data Supplement). The
media thickness and the ratio of media thickness to lumen diameter
were signiﬁcantly increased in aorta, renal artery and mesentery artery
of the rats with salusin-β overexpression. Moreover, the lumen diame-
ter of renal artery and mesentery artery was signiﬁcantly reduced
in rats with salusin-β overexpression (Fig. 5C and D). Masson’s
trichrome staining showed the increased adventitia thickness and colla-
gen content in the adventitia of arteries in the rats with salusin-β
overexpression.3.7. Signal molecules of vascular proliferation and ﬁbrosis in rats with
salusin-β overexpression
Salusin-β overexpression promoted the phosphorylation of CREB,
EGFR and ERK1/2, but had no signiﬁcant effect on the phosphorylation
of JNK and p38 in aorta, renal artery and mesentery artery of rats
(Fig. 6A,B). It increased the intracellular cAMP level (Fig. 6C) and the
PCNA and phosphorylated histone H3 levels (markers of proliferation)
in the media of aorta, renal artery and mesentery artery (Fig. S17, in
the online-only Data Supplement). The salusin-β overexpression in-
creased the collagen-I, collagen-III and ﬁbronectin mRNA expression
in these arteries of rats (Fig. 7A). Furthermore, it increased TGF-β1
and CTGF mRNA expressions and promoted the phosphorylation of
Smad2/3 in those arteries of rats (Fig. 7B,C).Fig. 6. Effects of salusin-β overexpression on phosphorylation and cAMP levels in aorta, renal ar
rats received PBS (Ctrl), lentivirus expressing GFP (Vector), or lentivirus expressing both GFP an
ERK and p38, n = 3 for each group; C, cAMP levels, n = 6 for each group; D, representative
(Thr202/Tyr204) and p38 (Thr180/Tyr182); Values are mean ± SE. *P b 0.05 vs. Ctrl; †P b 0.053.8. Salusin-β overexpression-induced hypertension in rats
Salusin-β overexpression caused a severe and long-lasting hyper-
tension accompanied by tachycardia in rats. SBP in conscious rats was
signiﬁcantly increased since the 3rd day after the salusin-β gene trans-
fer, reached its maximum at the end of the 2ndweek andmaintained at
very high level from this time on. HR in conscious rats was signiﬁcantly
increased since the 2nd week after the salusin-β gene transfer (Fig. 7E).
Hypertension and tachycardia were further conﬁrmed by the measure-
ment of carotid MAP and HR under anaesthesia (Fig. S18, in the online-
only Data Supplement).
3.9. Effects of intravenous injection of salusin-β on blood pressure in rats
Intravenous injection of salusin-β (0.0001-0.01 nmol/kg) signiﬁ-
cantly increased MAP, but had no signiﬁcant effect on HR. The maximal
pressor response was observed at the dose of 0.01 nmol/kg of salusin-β,
lasting about 20 min and reaching its maximum at 5 min. However, in-
travenous injection of very high dose of salusin-β (1000 pmol/kg)
caused immediate and rapid decreases in both MAP and HR (Figs. S19,
S20, in the online-only Data Supplement).
4. Discussion
VSMCs proliferation and vascularﬁbrosis are two important changes
in vascular remodeling and stiffening, and act as impetus for the initia-
tion and progression of some cardiovascular diseases including hyper-
tension, atherosclerosis, stroke, diabetic angiopathy [1,2,21]. Arterialtery andmesentery artery of rats. All themeasurements were carried out 4weeks after the
d salusin-β (Salusin-β). A, phosphorylation of CERB, EGFR and JNK; B, phosphorylation of
images of phosphorylation of CREB (Ser133), EGFR (Thr654), JNK (Thr183/Tyr185), ERK
vs. Vector.
Fig. 7. Effects of salusin-β overexpression on the ﬁbrosis of arteries, systolic blood pressure (SBP) and heart rate (HR) in rats. The measurements of mRNA levels and Smad protein were
carried out 4 weeks after the rats received PBS (Ctrl), lentivirus expressing GFP (Vector), or lentivirus expressing both GFP and salusin-β (Salusin-β). A, collagen-I, collagen-III and ﬁbro-
nectinmRNA expression; B, TGF-β1 and CTGFmRNA expression; C, phosphorylation of Smad2/3 (Ser423/425, 60/52KDa). n=4 for each group; D, representative images ofWestern blot;
E, effects of salusin-β overexpression on systolic blood pressure (SBP) and heart rate (HR) in conscious rats. n = 4 for each group. Values are mean ± SE. *P b 0.05 vs.Ctrl; †P b 0.05 vs.
Vector.
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as myocardial hypertrophy, myocardial infarction, stroke, renal failure,
dementia, and a hallmark of the aging process [22–25]. This study re-
vealed the roles and signal pathways of salusin-β in VSMCs prolifera-
tion, vascular ﬁbrosis and maladaptive vascular remodeling. Moreover,
we found that salusin-β overexpression elicited severe hypertension.
These ﬁndings suggest that intervention of salusin-βmay be a strategy
for preventing the excessive vascular proliferation and ﬁbrosis in hyper-
tension, atherosclerosis and diabetes.
Salusin-β is known to induce mitogenesis of human VSMCs and in-
crease intracellular cAMP concentration [7]. CREB acts as a principalme-
diator in cAMP-dependent PKA phosphorylation [26]. We found that
salusin-β stimulated the human VSMCs proliferation in vitro, which
was further conﬁrmed by the increased cell populations in the S phase
and the increased ratio of EdU-positive cells to total cells. Salusin-β
overexpression in rats reduced the lumen diameter of renal andmesen-
tery arteries, increased themedia thickness and the ratio ofmedia thick-
ness to lumen diameter, and stimulated the protein expressions of
proliferation markers (PCNA and phosphorylated histone H3) in the
media of these arteries. The results indicate that long-lasting increased
salusin-β induces vascular proliferation and remodeling in vivo. The
VSMCs proliferation effect of salusin-βwas abolished by an AC inhibitor
SQ22536, a PKA inhibitor Rp-cAMP or a CREB inhibitor KG501. Salusin-β
increased intracellular cAMP levels in VSMCs. It promoted the
phosphorylation of PKA and CREB in VSMCs, which were abolished
by SQ22536. Moreover, the CREB phosphorylation effect of salusin-β
was prevented by Rp-cAMP. These results indicate that cAMP-PKA de-
pendent CREB phosphorylation mediates salusin-β-induced human
VSMCs proliferation, which is conﬁrmed by the ﬁndings that salusin-β
overexpression increased cAMP levels and promoted the CREB phos-
phorylation in rats.
The p38MAPK andMAPKAPK-2were involved in Ang II-induced Akt
activation in vascular smooth muscle cells [27]. We found that thesalusin-β-induced VSMCs proliferation was prevented by ERK inhibitor
U0126 rather than JNK inhibitor SP600125 or p38 inhibitor SB203580.
Salusin-β promoted the ERK1/2 phosphorylation, which was abolished
by the AC inhibitor and PKA inhibitor. However, salusin-β had no signif-
icant effects on the JNK and p38 phosphorylation. Salusin-β overexpres-
sion increased the ERK1/2 phosphorylation but not the JNK and p38
phosphorylation in the arteries of rats. These results indicate that
cAMP-PKA dependent ERK1/2 activation mediates salusin-β-induced
VSMCs proliferation. The ERK1/2 phosphorylation appears to approach
the normal level after several hours following salusin-β administration.
We speculate that the ERK1/2 phosphorylation may act as a regulatory
switch for downstream signal pathways.
EGFR is a cell surface receptor for epidermal growth factor family of
extracellular protein ligands. Activation of EGFR is associated with cell
proliferation [28]. Transactivation of EGFR regulates the activities of
ERK1/2 induced by Ang II in VSMCs [29]. Co-transactivation of EGFR
contributes to Ang II-induced VSMCs proliferation [30]. We found that
EGFR tyrosine kinase inhibitor AG1478 abolished the salusin-β-
induced proliferation and phosphorylation of CREB and ERK1/2 in
VSMCs. Moreover, salusin-β promotes EGFR phosphorylation, which
was abolished by AC inhibitor SQ22536 or PKA inhibitor Rp-cAMP.
These results indicated that the transactivation of EGFR mediates
cAMP/PKA induced ERK1/2 and CREB activation and leads to prolifera-
tion signal of salusin-β in VSMCs. The results were further supported
by the ﬁndings that the salusin-β overexpression increased the ratio
of phosphorylated EGFR to total EGFR in arteries of rats. Heparin-
binding EGF-like growth factor (HB-EGF) is recognized as a ligand
that binds to EGFR [31]. HB-EGF is highly expressed in VSMCs
and has been shown to stimulate proliferation of VSMCs via auto-
phosphorylation of EGFR [32]. We found that anti-HB-EGF IgG
prevented the salusin-β-induced VSMCs proliferation, attenuated the
salusin-β-induced EGFR phosphorylation, and abolished the salusin-β-
induced phosphorylation of CREB and ERK. These results suggest a
1717H.-J. Sun et al. / Biochimica et Biophysica Acta 1852 (2015) 1709–1718critical role of HB-EGF in mediating salusin-β-induced EGFR phosphor-
ylation and the following proliferation of VSMCs.
Vascular ﬁbrosis is known to involve in the accumulation of ECM
proteins, particularly collagen and ﬁbronectin, and contributes to struc-
tural remodeling [33]. Excessive collagen or reduced elastin in the vas-
cular wall leads to vascular ﬁbrosis and increased stiffness [34]. We
found that salusin-β increased collagen-I, collagen-III and ﬁbronectin
mRNAexpression (markers ofﬁbrosis [35]) in VSMCs. Salusin-β overex-
pression in rats increased these ECM proteins and collagen contents in
the arteries. These results indicate that salusin-β induces vascular
ﬁbrosis.
TGF-β1 is a multifunctional cytokine related to cell growth and dif-
ferentiation, matrix production and ﬁbrosis [36,37]. CTGF is a down-
stream mediator of TGF-β1, and TGF-β1-induced CTGF expression is
regulated by the Smad pathway [33,38]. CTGF is implicated in vascular
remodeling by upregulation of extracellular matrix (ECM) [33,39], and
CTGF overexpression promotes VSMCs to express more ECM protein
[40]. We found that salusin-β increased TGF-β1 and CTGF mRNA
expression, and promoted Smad 2/3 phosphorylation, which were
abolished by ALK5 inhibitor A83-01 in VSMCs. A83-01 abrogated
salusin-β-induced ECM synthesis. Moreover, salusin-β overexpression
increased TGF-β1, CTGF, collagen I, collagen III and ﬁbronectin mRNA
expressions and the Smad2/3 phosphorylation in arteries of rats.
These results indicate that salusin-β is a potent pro-ﬁbrotic factor in
vascular ﬁbrosis, and CTGF-mediated ECM synthesis via TGF-β1/
Smad2/3 signal pathway plays a major role in the salusin-β-induced
vascular ﬁbrosis. On the other hand, anti-TGF-β1 IgG almost abolished
the effects of salusin-β on collagen-I, collagen-III and ﬁbronectin
mRNA expressions as well as Smad2/3 phosphorylation in VSMCs, sug-
gesting that TGF-β1 is necessary for mediating salusin-β-induces ECM
deposition and ﬁbrosis.
Salusin-α suppresses while salusin-β stimulates foam cell forma-
tion, and decreased salusin-α and/or increased salusin-β may be a
promising candidate biomarker for predicting atherosclerotic cardio-
vascular diseases [41]. An interesting question is whether the prolifera-
tion and ﬁbrosis effects of salusin-β in VSMCs could be attenuated by
salusin-α. We found that salusin-α induced a weaker VSMCs prolifera-
tion than salusin-β and augmented the proliferation effects of salusin-β,
while salusin-α had no signiﬁcant effect on ﬁbrosis but attenuated the
effects of salusin-β in human VSMCs. The mechanism of salusin-α re-
mains a further investigation. It is noted that the effects of salusin-α is
only tested in human VSMCs and not in the rats because there is a big
difference in human salusin-α and rat salusin-α [8].
Salusin-β is recognized as a bioactive peptide with peripheral
hypotensive and bradycardic effects [7]. It is unexpected that salusin-
β overexpression in the present study caused a severe and long-
lasting hypertension accompanied with tachycardia. The mean plasma
salusin-β levels were about 0.007 nmol/L in normal rats and
0.041 nmol/L in salusin-β overexpression rat, which were similar to
the previously reported levels in control rats (0.008 nmol/L) and
renovascular hypertensive rats (0.031 nmol/L) [10]. It is noted that
the peripheral hypotensive and bradycardic effects of salusin-β in
the previous study were induced by intravenous injection of 0.1-
1 nmol/Kg of salusin-β in rats, while 0.1 nmol/Kg of salusin-β only in-
duced a tendency of a slight decline followed by a slight increase in
blood pressure [7]. These doses of salusin-β used for inducing depressor
and bradycardic responses were much higher than the physiological or
pathological plasma salusin-β level in rats. We found that intravenous
injection of salusin-βwith the dose of 0.0001, 0.001 or 0.01 nmol/kg sig-
niﬁcantly increased, rather than reduced blood pressure in rats. Only
very high dose of salusin-β (1 nmol/Kg) induced potent depressor and
bradycardic responses in rats, similar to previous study [7]. We con-
clude that salusin-β in physiological or pathological levels increases
blood pressure, but very high dose of salusin-β reduces blood pressure.
Although the hypotensive and bradycardic effects of very high dose of
salusin-β is known to be mediated by its negative chronotropic andinotropic roles in heart [7,42], the underlying mechanism about the
pressor effect of salusin-β is unknown.
A limitation of the present study is that no chemicals for inhibiting or
blocking salusin-β was used in the present study because selective in-
hibitor or antagonist aimed at salusin-β is not available until now.
Moreover, receptors of salusin-β are not identiﬁed. It is known that de-
creased salusin-α level in plasma and vascular tissues are closely linked
with human atherosclerosis, while salusin-β contributes to the patho-
genesis of atherosclerosis [43,44]. We found that the proliferation and
ﬁbrosis effects of salusin-β in VSMCs were abolished by anti-salusin-β
IgG, and not by anti-salusin-α IgG. Similarly, the proliferation effect of
salusin-α in VSMCs was abolished by anti-salusin-α IgG, and not by
anti-salusin-β IgG. The results indicate the speciﬁcity of anti-salusin-α
IgG and anti-salusin-β IgG and the effectiveness of these IgG in the neu-
tralization of salusin-α or salusin-β. Although salusin-β is found to play
important roles in stimulating the VSMCs proliferation and ﬁbrosis in
pathological state, the neutralization of endogenous salusin-α or
salusin-β with corresponding IgG had no signiﬁcant effects on the
VSMCs proliferation and ﬁbrosis in the physiological state. On the
other hand, the effects of salusin-β on the endothelial cells and vascular
function remain a further investigation.
5. Conclusion
Plasma salusin-β levelswere distinctly higher in subjectswith diabe-
tes, coronary artery disease and cerebrovascular disease than healthy
controls [13]. Enhanced salusin-β expression contributes to progression
of atherosclerosis in low-density lipoprotein receptor deﬁcientmice [45,
46]. Serum salusin-β concentrationwas higher in patientswith essential
hypertension, andwas positively correlatedwith the bodymass, systolic
and diastolic blood pressure [47]. This study indicates that salusin-β in-
duces VSMCs proliferationmediated by cAMP-PKA-dependent CREB ac-
tivation concomitant to ERK1/2 activation via transactivation of EGFR.
Salusin-β is a pro-ﬁbrotic factor via stimulating CTGF production, ECM
synthesis and vascular ﬁbrosis, which is mediated by TGF-β1/Samd sig-
nal pathway. The VSMCs proliferation effect of salusin-β is augmented
by salusin-α, but the ﬁbrosis effect is attenuated by salusin-α. Persistent
increased salusin-β causes severe hypertension and vascular remodel-
ing including VSMC proliferation and ﬁbrosis. This study reveals the
important roles of salusin-β in vascular proliferation, ﬁbrosis and re-
modeling and hypertension. Intervention of salusin-βmay be a thera-
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